当前位置: X-MOL 学术Biomolecules › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fibrinogen Fucosylation as a Prognostic Marker of End-Stage Renal Disease in Patients on Peritoneal Dialysis.
Biomolecules ( IF 4.8 ) Pub Date : 2020-08-09 , DOI: 10.3390/biom10081165
Marko Baralić 1 , Nikola Gligorijević 2 , Voin Brković 1 , Jaroslav Katrlík 3 , Lucia Pažitná 3 , Miloš Šunderić 2 , Goran Miljuš 2 , Ana Penezić 2 , Zorana Dobrijević 2 , Mirjana Laušević 1, 4 , Olgica Nedić 2 , Dragana Robajac 2
Affiliation  

Glycosylation may strongly affect protein structure and functions. A high risk of cardiovascular complications seen in patients with end-stage renal disease (ESRD) is, at least partly associated with delayed clot formation, increased clot strength, and delayed cloth lysis. Taking into consideration that fibrinogen mediates these processes, we isolated fibrinogen from the plasma from patients with ESRD on peritoneal dialysis (ESRD-PD), and examined glycosylation of native fibrinogen and its subunits by lectin-based microarray and lectin blotting. Compared to healthy controls, fibrinogen from patients had increased levels of A2BG2 and decreased levels of FA2 glycan. The distribution of glycans on individual chains was also affected, with the γ chain, responsible for physiological functions of fibrinogen (such as coagulation and platelet aggregation), being most prone to these alterations. Increased levels of multi-antennary N-glycans in ESRD-PD patients were also associated with the type of dialysis solutions, whereas an increase in the fucosylation levels was strongly related to the peritoneal membrane damage. Consequently, investigation of fibrinogen glycans can offer better insight into fibrinogen-related complications observed in ESRD-PD patients and, additionally, contribute to prognosis, choice of personalised therapy, determination of peritoneal membrane damage, and the length of utilization of peritoneum for dialysis.

中文翻译:


纤维蛋白原岩藻糖基化作为腹膜透析患者终末期肾病的预后标志物。



糖基化可能强烈影响蛋白质的结构和功能。终末期肾病 (ESRD) 患者出现心血管并发症的高风险至少部分与血栓形成延迟、血栓强度增加和布溶解延迟有关。考虑到纤维蛋白原介导这些过程,我们从腹膜透析终末期肾病 (ESRD-PD) 患者的血浆中分离出纤维蛋白原,并通过基于凝集素的微阵列和凝集素印迹检查天然纤维蛋白原及其亚基的糖基化。与健康对照相比,患者的纤维蛋白原 A2BG2 水平升高,FA2 聚糖水平降低。聚糖在各个链上的分布也受到影响,其中负责纤维蛋白原生理功能(例如凝血和血小板聚集)的 γ 链最容易发生这些变化。 ESRD-PD 患者中多触角 N-聚糖水平的增加也与透析溶液的类型相关,而岩藻糖基化水平的增加与腹膜损伤密切相关。因此,纤维蛋白原聚糖的研究可以更好地了解 ESRD-PD 患者中观察到的纤维蛋白原相关并发症,此外,还有助于预后、个性化治疗的选择、腹膜损伤的确定以及腹膜透析的使用时长。
更新日期:2020-08-10
down
wechat
bug